Gastrointestinal Cancer News

New 3D imaging technology developed at University of Michigan enables real-time measurement of radiation treatment, enhancing precision and potentially minimizing off-target effects.

A phase 3 trial of trilaciclib in combination FOLFOXIRI and bevacizumab for patients with metastatic colorectal cancer met its co-primary endpoints but will be terminated based on early efficacy data, according to the agent’s manufacturer.

Data from a pair of single-arm clinical trials will be sufficient to illustrate the benefits and risks of dostarlimab-gxly for a subgroup of patients with rectal cancer, according to the FDA’s Oncologic Drugs Advisory Committee.

Among patients with solid tumors, septic shock was associated with a 69.4% 28-day mortality rate, according to a study published in CHEST.

High BMI appeared associated with increased risk for any-grade immune-related adverse events among a cohort of patients with advanced cancer undergoing treatment with immune checkpoint inhibitors.

In a video interview, Benjamin Schlechter, MD, of Dana-Farber Cancer Institute, spoke about two presentations on using radiation palliatively presented at ASCO Gastrointestinal Cancers Symposium.

Benjamin Schlechter, MD, of Dana-Farber Cancer Institute, discussed the mature phase 3 data on the addition of bevacizumab to trifluridine/tipiracil in refractory colorectal cancer in a video interview with Healio.

In a video interview, Benjamin Schlechter, MD, talked about a “fascinating, compelling and important study” that looked at liposomal irinotecan injection regimen vs. nab-paclitaxel and gemcitabine in metastatic pancreatic cancer.

Researchers at Cold Spring Harbor Laboratory have developed software that correctly deduces continental ancestry from tumor DNA and RNA.

Benjamin Schlechter, MD, of Dana-Farber Cancer Institute, discussed a trial-in-progress investigating autologous T-cell antigen coupler T cells targeting HER2 in relapsed or refractory solid tumors in a video interview with Healio.